Lead Optimization of 2-((4-fluorophenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methyl)-6-methoxyphenol as GSK3β Inhibitors for Alzheimer’s Disease Therapeutics Targeting Tauopathy, and Neuroinflammation: In-silico design, Synthesis, and Biological Evaluation

Accessibility Controls

Implementing Organization

Indian Institute of Science

Principal Investigator

Dr. Hari Madhav

Indian Institute Of Science, Karnataka

harimadhavgautam@gmail.com

CO-Principal Investigator

Nil

Related Research

View All

Funding Organization

Anusandhan National Research Foundation (ANRF)

Quick Information

Area of Research

Chemical Sciences

Focus Area

Organic Chemistry, Medicinal Chemistry

Start Date

01 Apr 2024

End Date

31 Mar 2026

Status

ongoing

Output

No. of Research Paper

Technologies (If Any)

No. of PhD Produced

Publications

No. of Patents

Filed : 00

Grant : 00

Accessibility Controls

Research Projects

Lead Optimization of 2-((4-fluorophenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methyl)-6-methoxyphenol as GSK3β Inhibitors for Alzheimer’s Disease Therapeutics Targeting Tauopathy, and Neuroinflammation: In-silico design, Synthesis, and Biological Evaluation

Implementing Organization

Related Research

Funding Organization

Quick Information

Output

विज्ञान एवं प्रौद्योगिकी विभाग

Department of
Science and Technology

Accessibility Controls

Research Projects

Lead Optimization of 2-((4-fluorophenyl)(4-(pyrazin-2-yl)piperazin-1-yl)methyl)-6-methoxyphenol as GSK3β Inhibitors for Alzheimer’s Disease Therapeutics Targeting Tauopathy, and Neuroinflammation: In-silico design, Synthesis, and Biological Evaluation

Implementing Organization

Related Research

Funding Organization

Quick Information

Output

You are leaving this website